—
C+
C+ The full Closelook — membership. Open the C+ overview

Curaleaf Holdings Inc. (CURA.TO) — Quality & forensics

As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

31 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

0.91 Altman Z-Score

Sits in the distress zone (below 1.81). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

3/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

-2.72 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.

Continue: the CURA.TO chart & overview

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Curaleaf Holdings Inc.'s Closelook quality reading?

The composite reads 31/100 across 7 modules, as of 2026-09-18: valuation 26, quality 22, growth 38, balance sheet 22, cash quality 35, capital allocation 17, momentum 65. Closelook scores are research diary readings, not ratings or investment advice.

What is Curaleaf Holdings Inc.'s Altman Z-Score?

0.91, which sits in the distress zone (below 1.81) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Curaleaf Holdings Inc.'s Piotroski F-Score?

3 of 9, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Curaleaf Holdings Inc.'s Beneish M-Score indicate?

-2.72 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.